60 Degrees Pharmaceuticals Stock Set to Reverse Split on Tuesday, January 20th (NASDAQ:SXTP)

60 Degrees Pharmaceuticals Inc. (NASDAQ:SXTP) shares are scheduled to reverse split on the morning of Tuesday, January 20th. The 1-4 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, January 19th.

60 Degrees Pharmaceuticals Trading Down 2.4%

Shares of SXTP opened at $0.47 on Friday. The business’s 50-day moving average price is $0.84 and its 200 day moving average price is $1.29. The stock has a market capitalization of $1.97 million, a P/E ratio of -0.13 and a beta of 2.98. 60 Degrees Pharmaceuticals has a 1-year low of $0.34 and a 1-year high of $6.00.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($1.21) by $0.55. The firm had revenue of ($0.01) million for the quarter, compared to analysts’ expectations of $0.38 million. On average, research analysts predict that 60 Degrees Pharmaceuticals will post -5.09 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Ascendiant Capital Markets decreased their price objective on shares of 60 Degrees Pharmaceuticals from $3.00 to $2.80 and set a “buy” rating for the company in a research note on Friday, November 28th. Weiss Ratings restated a “sell (e+)” rating on shares of 60 Degrees Pharmaceuticals in a report on Monday, December 29th. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of 60 Degrees Pharmaceuticals in a research report on Friday, November 14th. Finally, Zacks Research raised 60 Degrees Pharmaceuticals to a “hold” rating in a research report on Tuesday, November 18th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $4.40.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.